Announcements
Announcement for the appointment of Corporate Governance Officer of the Company
1.Type of personnel changed (please enter: spokesperson, acting spokesperson, important personnel (CEO, COO, CMO, CSO, etc.), financial officer, accounting officer, corporate governance officer, chief information security officer, research and development …
The Company’s BOD resolved the plan to disperse shareholding of AP Biosciences
1.Date of occurrence of the event:2023/03/13 2.Company name: OBI Pharma Inc. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Head office 4.Reciprocal shareholding ratios: N/A 5.Cause of occurrence: To …
The Company’s Board of Directors resolved to convene the 2023 Annual General Shareholders’ Meeting
1.Date of the board of directors resolution:2023/03/13 2.General shareholders’ meeting date:2023/06/27 3.General shareholders’ meeting location: Masterlink Securities Education and Training Center(11F., No.97, Sec. 2, Dunhua S. Rd., Taipei City) 4.Shareholders …
Announcement of 2022 Consolidated Financial Statements were approved by the Board of Directors
1.Date of the board of directors submitted or approved:2023/03/13 2.Date of the audit committee approved:2023/03/10 3.Start and end dates of financial reports or unaudited financial information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):2022/01/01~2022/12/31 …
Announcement on behalf of AP Biosciences of not Distributing Dividends of 2022
1.Date of the board of directors resolution:2023/03/07 2.Type and monetary amount of dividend distribution: The Board of Directors of AP Biosciences resolved not to distribute dividends of 2022. 3.Any other …
Announcement on behalf of AP Biosciences that the BOD resolved to convene the 2023 Annual General Shareholders’ Meeting
1.Date of the board of directors resolution:2023/03/07 2.General shareholders’ meeting date:2023/05/23 3.General shareholders’ meeting location: Building A. 2F., No. 19-10, Sanchong Rd., Nangang Dist., Taipei City (Conference room located on …
The first-in-class novel prodrug, OBI-3424, has been granted by TFDA to proceed to Phase II clinical trial
1.Date of occurrence of the event:2023/02/16 2.New drug name or code: first-in-class novel prodrug, OBI-3424 3.Indication: OBI-3424 is converted into a potently cytotoxic DNA alkylating agent specifically by the AKR1C3 …
OBI filed application for Phase II human clinical trial of first-in-class novel prodrug, OBI-3424, to TFDA
1.Date of occurrence of the event:2023/02/02 2.New drug name or code: first-in-class novel prodrug, OBI-3424 3.Indication: OBI-3424 is converted into a potently cytotoxic DNA alkylating agent specifically by the AKR1C3 …
Announcement on behalf of AP Biosciences that application for Phase I human clinical trial of Bispecific Antibody, AP505, has been granted by US FDA
1.Date of occurrence of the event: 2023/01/14 2.New drug name or code: Bispecific Antibody, AP505 3.Indication: Bispecific antibody AP505 is a novel cancer immunotherapy developed by AP Biosciences (hereinafter referred …
Announcement of BOD’s resolution to lift the non-competition restrictions for new CEO
1.Date of the board of directors resolution: 2022/12/30 2.Name and title of the managerial officer with permission to engage in competitive conduct: Yun Yen / CEO of the Company (represent …